Assenagon Asset Management S.A. Has $12.94 Million Stock Holdings in Caribou Biosciences, Inc. (NASDAQ:CRBU)

Assenagon Asset Management S.A. lowered its position in Caribou Biosciences, Inc. (NASDAQ:CRBUFree Report) by 14.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,258,539 shares of the company’s stock after selling 390,043 shares during the quarter. Assenagon Asset Management S.A. owned 2.55% of Caribou Biosciences worth $12,941,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in CRBU. Avidity Partners Management LP increased its position in Caribou Biosciences by 119.3% in the 3rd quarter. Avidity Partners Management LP now owns 6,050,212 shares of the company’s stock valued at $28,920,000 after acquiring an additional 3,291,612 shares during the period. BlackRock Inc. increased its holdings in Caribou Biosciences by 0.7% in the first quarter. BlackRock Inc. now owns 4,754,563 shares of the company’s stock valued at $25,247,000 after purchasing an additional 32,480 shares during the period. Vanguard Group Inc. raised its position in Caribou Biosciences by 49.3% during the 3rd quarter. Vanguard Group Inc. now owns 3,822,151 shares of the company’s stock worth $18,270,000 after purchasing an additional 1,261,920 shares during the last quarter. Deerfield Management Company L.P. Series C acquired a new position in Caribou Biosciences during the 3rd quarter worth about $16,730,000. Finally, State Street Corp grew its position in shares of Caribou Biosciences by 4.9% in the 1st quarter. State Street Corp now owns 3,355,292 shares of the company’s stock valued at $17,817,000 after buying an additional 156,399 shares during the last quarter. Institutional investors own 77.51% of the company’s stock.

Caribou Biosciences Stock Up 0.4 %

Shares of NASDAQ CRBU opened at $5.14 on Friday. The company has a market capitalization of $464.22 million, a PE ratio of -3.54 and a beta of 2.59. Caribou Biosciences, Inc. has a twelve month low of $3.44 and a twelve month high of $8.59. The firm has a fifty day simple moving average of $6.37 and a 200 day simple moving average of $5.54.

Wall Street Analyst Weigh In

Separately, HC Wainwright raised their price objective on Caribou Biosciences from $23.00 to $24.00 and gave the stock a “buy” rating in a research report on Tuesday, March 19th.

Check Out Our Latest Stock Analysis on Caribou Biosciences

Caribou Biosciences Profile

(Free Report)

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma.

Recommended Stories

Institutional Ownership by Quarter for Caribou Biosciences (NASDAQ:CRBU)

Receive News & Ratings for Caribou Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caribou Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.